If the coronary vaccine developed by the pharmaceutical company AstraZeneca and the University of Oxford cannot be given to people over 65, it would automatically slow down compliance with the Finnish vaccination program, says Hanna Nohynek, chief physician of the National Institute for Health and Welfare (THL).
According to Nohynek, the schedule for vaccinating the Finnish adult population against the coronavirus depends on the vaccine and its deliveries from AstraZeneca and the University of Oxford.
- We will definitely be better on the map later this afternoon, Nohynek told STT from the early afternoon.
The European Medicines Agency (EMA) is expected to report today on the outcome of its application for a marketing authorization for the coronary vaccine developed by AstraZeneca and the University of Oxford.
According to Nohynek, the Finnish national vaccination expert group will meet next week to discuss the Finnish Medicines Agency's decision and future vaccine doses in Finland.
- We are now waiting for the EMA's marketing authorization decision and then we will discuss how Finland will react to it.
Usually the aim is to use vaccines according to the marketing authorization, that is the starting point.
But on the other hand, it is known that AstraZeneca’s vaccine is already being used in the UK for people of all ages.
According to Nohynek, it is important to see all the information that the marketing authorization recommendation has had in place when making the decision.
If the Agency ends up recommending the granting of a marketing authorization, the matter will be referred to the EU Commission, which is in charge of granting the marketing authorization.
The German vaccine authorities said yesterday that they would only recommend the administration of AstraZeneca to people under 65 years of age.
The reason, according to the German Vaccine Commission, is that not enough information is yet available on the effectiveness of the vaccine in people over 65 years of age.